Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC-ER PK and Food Effect Study
NCT05232461Phase 1Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- Apr 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PrimeC in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by NeuroSense Therapeutics. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration at 1 month, Area Under the Curve from time 0 to infinity at 1 month and 1 more. Started Apr 2022; status: completed.
02
Drugs
PrimeC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05232461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232461.